EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting HMGB1 in the Treatment of Non-Small Cell Lung Adenocarcinoma

Brady Anderson, Mary Vue, Nya Gayluak, Sarah Jane Brown, Lynne T. Bemis, Glenn E. Simmons

Onco · 2021

DOI: 10.3390/onco1010004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Onco, 2021. Verfasst von Brady Anderson und 5 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Center for Advancing Translational Sciences.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Evidence of immunogenic cell death as a predictor of response to cancer therapy has increased interest in the high molecular group box 1 protein (HMGB1). HMGB1 is a nuclear protein associated with chromatin organization and DNA damage repair. HMGB1 is also a damage-associated molecular pattern (DAMP) protein and promotes proinflammatory signaling in a paracrine and autocrine manner. Extracellular HMGB1 can promote activation of NF-kB and is associated with several chronic inflammatory and autoimmune diseases, including sepsis, rheumatoid arthritis, atherosclerosis, chronic kidney disease, systemic lupus erythematosus (SLE), as well as cancer. In this review, we describe studies that demonstrate the use of deacetylase inhibitors and HMGB1 inhibitors to alter the expression and localization of HMGB1 in cancer cells, with a focus on lung cancer. The drugs described herein are well established and frequently used in human and small mammal studies. The main objective of this review is to summarize the potential benefit of targeting posttranslational modification of HMGB1 to decrease inflammatory signaling in the tumor microenvironment, and perhaps lead to improved response to current immunotherapeutic approaches.

Förderung

  • National Center for Advancing Translational Sciences

Zitieren

APA

Anderson, B., Vue, M., Gayluak, N., Brown, S. J., Bemis, L. T., & Simmons, G. E. (2021). Targeting HMGB1 in the Treatment of Non-Small Cell Lung Adenocarcinoma. Onco. https://doi.org/10.3390/onco1010004

Vancouver

Anderson B, Vue M, Gayluak N, Brown SJ, Bemis LT, Simmons GE. Targeting HMGB1 in the Treatment of Non-Small Cell Lung Adenocarcinoma. Onco. 2021. doi:10.3390/onco1010004

BibTeX
@article{Anderson2021,
  author = {Anderson, Brady and Vue, Mary and Gayluak, Nya and Brown, Sarah Jane and Bemis, Lynne T. and Simmons, Glenn E.},
  title = {Targeting HMGB1 in the Treatment of Non-Small Cell Lung Adenocarcinoma},
  journal = {Onco},
  year = {2021},
  doi = {10.3390/onco1010004}
}
Kostenlos starten →